Fluorescent Virus-Like Particle (VLP) Protein Isotype Control
Cat# C30H-100ug
Size : 100ug
Brand : Novoprotein
Contact local distributor :
Phone : +1 850 650 7790
Description - Recombinant Fluorescent Virus-Like Particle (VLP) Protein Isotype Control is produced by our Mammalian expression system and is formed by self-assembly of envelop/capsid proteins from viruses. And Fluorescent VLP Protein Isotype Control can be used as isoytype control for Fluorescent VLPs displaying membrane proteins in various applications.
- Conjugate:EGFP
- Excitation source: 488 nm spectral line, argon-ion laser
- Excitation Wavelength: 488 nm
- Emission Wavelength: 530 nm
Known As VLP; Virus Like Particle; eVLP; VLPs
Formulation Description Supplied as a 0.2 μm filtered solution of PBS, 30% Trehalose, pH 7.4.
Endotoxin < 1 EU/µg as determined by LAL test.
Purity-SEC-HPLC 
Greater than 95% as determined by SEC-HPLC. (QC verified) Shipping - The product is shipped on dry ice/polar packs.
- Upon receipt, store it immediately at the temperature listed below.
Storage - Store at ≤-70°C, stable for 12 months under sterile conditions.
- Please minimize freeze-thaw cycles.
Background Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting the host cell. Expression and self-assembly of the viral structural proteins can take place in various living or cell-free expression systems after which the viral structures can be assembled and reconstructed. VLPs are gaining in popularity in the field of preventive medicine and to date, a wide range of VLP-based candidate vaccines have been developed for immunization against various infectious agents, the efficacy of which is being evaluated. VLPs are highly immunogenic and are able to elicit both the antibody- and cell-mediated immune responses by pathways different from those elicited by conventional inactivated viral vaccines.